TNXP presenting Phase 3 and Phase 2 study results on Friday evening and Sat. evening. Also check out the massive insider buys in the $4.00 to almost $5.00 range recently. Get ready for some big green days next week. Info is below on the times of the presentations.
Tonix Pharmaceuticals will Present Phase 3 HONOR and Phase 2 AtEase Study Results in Poster Presentations at CNS Summit 2018
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced today that it will be presenting findings and retrospective analyses from the Phase 3 HONOR study and Phase 2 AtEase Study in two posters at CNS Summit 2018 being held November 1-4, 2018, in Boca Raton, Fla.
Details of Poster Presentation #1
Title: Differential Treatment Effects of TNX-102 SL*, a Sublingual Formulation of Cyclobenzaprine, on Dissociative Symptoms of Derealization and Depersonalization in a Military-Related PTSD Population: Retrospective Analysis of a Double-Blind Randomized Study
Date and Time: Friday, November 2, 2018, 5:00 p.m. – 7:00 p.m. ET
Poster Number: Board 8A
Presenter: Gregory M. Sullivan, M.D., Chief Medical Officer
Details of Poster Presentation #2
Title: Time Since Trauma in PTSD: Phase 3 Multi-Center, Double-Blind, Placebo-Controlled Trial of TNX-102 SL*, a Sublingual Formulation of Cyclobenzaprine, in Military-Related PTSD
Date and Time: Saturday, November 3, 2018, 5:00 p.m. – 7:00 p.m. ET
Poster Number: Board 8A
Presenter: Gregory M. Sullivan, M.D., Chief Medical Officer
*TNX-102 SL is an investigational New Drug and has not been approved for any indications.
About Tonix Pharmaceuticals Holding Corp.
Tonix is a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense through potential medical counter-measures. Tonix is developing Tonmya®#, which has been granted Breakthrough Therapy designation, as a bedtime treatment for PTSD. Tonix is also developing TNX-102 SL as a bedtime treatment for agitation in Alzheimer’s disease under a separate IND to support a Phase 2, potential pivotal, efficacy study and has been granted Fast Track designation by the FDA for this indication. TNX-601 (tianeptine oxalate) is in the pre-IND application stage, also for the treatment of PTSD but by a unique mechanism and designed for daytime dosing. Tonix’s lead biologic candidate, TNX-801, is a potential smallpox-preventing vaccine based on a live synthetic version of horsepox virus, currently in the pre-IND application stage.
#Tonmya has been conditionally accepted by the FDA as the proposed trade name for TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for PTSD.
